Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Brigham and Women's Hospital
Massachusetts General Hospital
Pharmacia
Information provided by (Responsible Party):
Peter C. Enzinger, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00137852
First received: August 29, 2005
Last updated: August 7, 2014
Last verified: August 2014

August 29, 2005
August 7, 2014
January 2002
November 2003   (final data collection date for primary outcome measure)
Response rate of combination of chemotherapy, radiation therapy and surgery in resectable esophageal carcinoma [ Time Frame: TBD ] [ Designated as safety issue: No ]
Response rate of combination of chemotherapy, radiation therapy and surgery in resectable esophageal carcinoma.
Complete list of historical versions of study NCT00137852 on ClinicalTrials.gov Archive Site
Determine the side effects of chemotherapy and radiation therapy in patients with resectable esophageal carcinoma [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
Determine the side effects of chemotherapy and radiation therapy in patients with resectable esophageal carcinoma.
Not Provided
Not Provided
 
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
Phase II Trial of Cisplatin, CPT-11, Celecoxib (PCC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer

This is a study for patients with resectable, locally advanced esophageal cancer. There is evidence to suggest that celecoxib in combination with cisplatin and irinotecan (CPT-11) may work well with radiation therapy to kill cancer cells. The primary goal is to develop a well-tolerated cancer treatment that has an acceptable response rate.

Patients will take celecoxib orally twice daily 3 days prior to radiation therapy and until one week prior to surgery. Celecoxib will then be restarted when the patient is discharged from the hospital following surgery and continued for 26 weeks.

Patients will receive chemotherapy (cisplatin and irinotecan) weekly on weeks 1, 2, 4 and 5 during radiation therapy. Chemotherapy must occur on or before the fifth day of radiation therapy.

Radiation therapy will be performed 5 days a week over a 5.6 week period.

Patients will undergo an esophagectomy within 4-8 weeks of chemotherapy/radiation therapy. Technically accessible lymph nodes will also be removed.

During chemotherapy/radiation therapy, a physical exam and bloodwork will be conducted weekly.

Between chemotherapy/radiation therapy and surgery a physical exam, bloodwork and CT of chest, abdomen, and pelvis should be performed.

After the completion of treatment and surgery, a physical exam and bloodwork should be done every 6 weeks for 6 months, then every 3 months for 1 1/2 years, then every 6 months for 3 years.

Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Esophageal Cancer
  • Drug: Cisplatin
    Given weekly on weeks 1, 2, 4 and 5 during radiation therapy.
  • Drug: Irinotecan
    Given weekly on weeks 1, 2, 4 and 5 during radiation therapy
    Other Name: CPT-11
  • Drug: Celecoxib
    Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.
  • Procedure: Radiation Therapy
    5 days a week for 5-6 weeks
  • Procedure: Esophagectomy
    Within 4-8 weeks of chemoradiation therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
35
December 2014
November 2003   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age greater than or equal to 18 years.
  • Adenocarcinoma or squamous cell carcinoma of the esophagus, including the gastroesophageal junction, histologically confirmed, American Joint Committee on Cancer (AJCC) Stage IIA, IIB, III. Additionally, patients with tumors of the lower thoracic esophagus and gastroesophageal junction may have regional lymph node involvement (M1A-Stage IVA), as long as the lymphadenopathy can be entirely encompassed by the radiation field.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Neutrophils greater than or equal to 1,500/ μL.
  • Platelets greater than or equal to 100,000/ μL.
  • Serum bilirubin less than or equal to 1.5 mg/dl.
  • Serum creatinine less than or equal to 1.5 mg/dl.
  • Aspartamine transaminase (AST or SGOT) less than or equal to 3x upper institutional normal limit.
  • Alkaline phosphatase less than or equal to 5x upper institutional normal limit.

Exclusion Criteria:

  • No prior surgery for esophageal or gastro-esophageal junction cancer.
  • No prior chemotherapy or radiation therapy.
  • Biopsy proven tumor invasion of the tracheobronchial tree or a tracheoesophageal fistula.
  • Metastatic disease to distant organs (e.g. liver, lungs, bone) or non-regional lymph nodes. Patients with supraclavicular/cervical lymph node involvement or patients with a proximal esophageal primary and celiac/gastro-hepatic lymph node involvement are also excluded.
  • Patients with co-morbid disease that, in the opinion of the investigator, makes combined chemo-radiotherapy inadvisable (e.g. New York State Grade III-IV heart disease, myocardial infarction in the last 4 months, uncontrolled infection, uncontrolled diabetes, uncontrolled hypertension, uncontrolled psychiatric illness or organ allograft(s) on immunosuppressive therapy).
  • Pregnant or lactating women or women of childbearing potential with either a positive or no pregnancy test at baseline.
  • Women of childbearing potential not using a reliable and appropriate contraceptive method. (Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.)
  • Other active malignancy (i.e. hematologic malignancy, metastatic solid tumor, or resected Stage I-IV solid tumor less than 3 years after resection).
  • Patients with known Gilbert's disease or interstitial pulmonary fibrosis.
  • Patients with prior severe reaction to nonsteroidal anti-inflammatory drugs (NSAIDs), sulfonamides, or celecoxib.
  • Patients with a history of seizure disorders who are receiving antiepileptic medication.
  • Positive malignant cytology of the pleura, pericardium or peritoneum.
  • Uncontrolled diarrhea (National Cancer Institute Common Toxicity Criteria [NCI CTC] greater than or equal to Grade 2).
  • Peripheral neuropathy (NCI CTC greater than or equal to Grade 2).
  • Symptomatic hearing loss, requiring a hearing aid or for which a hearing aid has been suggested by a health professional.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00137852
01-229
Not Provided
Peter C. Enzinger, MD, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
  • Brigham and Women's Hospital
  • Massachusetts General Hospital
  • Pharmacia
Principal Investigator: Peter C. Enzinger, MD Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP